HC Wainwright Has Positive Forecast for VRDN FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate to a loss of $3.58 per share from a projected loss of $4.28, while maintaining a Buy rating and $40 price target.
• Analyst sentiment is broadly positive: Viridian has a consensus “Moderate Buy” rating and average price target of $41, based on 11 Buy ratings and one Sell rating.
• Viridian’s latest quarter beat expectations, with an $0.81-per-share loss versus the $1.02-per-share consensus and revenue of $25.75 million versus estimates of $4.72 million.

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Thursday, November 5th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($3.58) for the year, up from their previous estimate of ($4.28). HC Wainwright currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for Viridian Therapeutics' Q4 2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.77) EPS, Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.76) EPS, FY2027 earnings at ($2.45) EPS, FY2028 earnings at ($1.09) EPS, FY2029 earnings at $1.26 EPS and FY2030 earnings at $4.14 EPS.

Several other equities research analysts also recently issued reports on the company. Wedbush lifted their price objective on Viridian Therapeutics from $41.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday. Needham & Company LLC increased their target price on Viridian Therapeutics from $34.00 to $38.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Wells Fargo & Company raised their price target on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the stock an "overweight" rating in a research report on Thursday. Weiss Ratings upgraded shares of Viridian Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, September 14th. Finally, Wall Street Zen upgraded shares of Viridian Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Saturday. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $41.00.

Viridian Therapeutics Stock Performance

Shares of VRDN opened at $28.49 on Monday. The company has a market capitalization of $3.24 billion, a P/E ratio of -7.42 and a beta of 1.07. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 14.46 and a current ratio of 14.46. The stock has a 50-day moving average price of $21.97 and a 200 day moving average price of $21.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative return on equity of 79.67% and a negative net margin of 1,620.79%. The business had revenue of $25.75 million for the quarter, compared to analyst estimates of $4.72 million.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new position in Viridian Therapeutics in the 2nd quarter worth about $33,000. KBC Group NV bought a new stake in shares of Viridian Therapeutics in the 1st quarter worth $34,000. State of Wyoming acquired a new stake in Viridian Therapeutics in the 2nd quarter valued at about $43,000. Fulcrum Asset Management LLP acquired a new stake in Viridian Therapeutics during the third quarter valued at approximately $97,000. Finally, Man Group plc bought a new stake in shares of Viridian Therapeutics during the 2nd quarter worth $197,000.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 2.40% of the company's stock.

Viridian Therapeutics News Summary

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.02-per-share estimate. The earnings beat, alongside optimism around the Lumvoa launch, has supported investor interest. Viridian Therapeutics Stock Rises 5% Despite Wider Q3 Loss
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Recent increases include Leerink Partners to $54, RBC to $41, Truist to $42, Wells Fargo to $34, Wedbush to $42 and HC Wainwright to $40. Zacks also noted a positive trend in earnings estimate revisions, though price targets are not guarantees. Zacks analyst outlook
• Neutral Sentiment: The company will present Phase 1 results for VRDN-008 and outline plans for its FcRn portfolio on November 9. The data and development plans could provide meaningful signals about the pipeline, but the outcome is not yet known. VRDN-008 conference call announcement

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company's lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian's pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.